Clinical Trial Update: Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating intrathecal administration of immune checkpoint inhibitors for leptomeningeal metastases associated with non-small cell lun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer with Leptomeningeal Metastases

Snippet

Sponsor: West China Hospital | Conditions: NSCLC Associated With Leptomeningeal Metastases | Phase 2 | Status: UNKNOWN